NCT04111705
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04111705 |
| Title | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) |
| Acronym | ORAKLE |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Intergroupe Francophone de Cancerologie Thoracique |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | FRA |
CKB BOOST